In the Claims:

This listing of claims will replace all prior versions and listings of claims in the present application. Amendments are shown by addition and ~~deletion~~ or [deletion].

1. (Currently amended) A compound of ~~the general~~ [f]Formulas 1 or 2:



Formula 1



Formula 2

wherein k and p are each 1, m and n are individually 0 or 1;

provided that if m is 1, then n is 0, and if n is 1, then m is 0;

Ar is pyridine, optionally substituted at any position with a substituent Z_j as defined below[.];

wherein Z_j refers to j number of Z substituents, which substituents can be present at any carbon atom on the azabicyclic ring,

j is 0, 1, or 2,

each Z is, individually, ~~a substituent species~~ selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, heterocyclyl, substituted heterocyclyl, cycloalkyl, substituted cycloalkyl, aryl ~~(including heteroaryl)~~, substituted aryl ~~(including heteroaryl)~~, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, -OR', -NR'R", $-CF_3$, -CN, $-NO_2$, -C≡C[$_2$]R', -SR', $-N_3$, -C(=O)NR'R", -NR'C(=O) R", -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R")$_j$C(=O)R', -O(CR'R")$_j$NR"C(=O)R', -O(CR'R")$_j$NR"SO_2R', -OC(=O)NR'R", -NR'C(=O)O R", -SO_2R', -SO_2NR'R", and -NR'SO_2R"[.];

where R' and R" are individually hydrogen, lower alkyl ~~(e.g., straight chain or branched alkyl including C_1-C_8, preferably C_1-C_6, such as methyl, ethyl, or isopropyl)~~, cycloalkyl, heterocyclyl, aryl, or arylalkyl ~~(such as benzyl)~~, and r is an integer from 1 to 6[,]; or R' and R" can combine with the atoms to which they are attached to form a ~~cyclic functionality~~ 3- to 7-membered saturated or unsaturated ring[,];

wherein ~~the term "substituted"~~ said ~~as applied to~~ alkyl, alkenyl, aryl ~~(including heteroaryl)~~, cycloalkyl, heterocyclyl, alkylaryl, and arylalkyl ~~and the like~~ ~~refers to~~ may be substituted with one or more ~~the~~ substituents ~~described above, starting with halo and ending with -NR'SO_2R"~~ selected from the group consisting of halo, -OR', -NR'R", -CF_3, -CN, -NO_2, -C≡CR', -SR', -N_3, -C(=O)NR'R", -NR'C(=O) R", -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R")$_0$C(=O)R', -O(CR'R")$_0$NR"C(=O)R', -O(CR'R")$_0$NR"SO_2R', -OC(=O)NR'R", -NR'C(=O)O R", -SO_2R', -SO_2NR'R", and -NR'SO_2R"[,];

where R' and R" individually are as defined;

R is hydrogen, unsubstituted lower alkyl, unsubstituted arylalkyl~~, acyl~~, unsubstituted alkoxycarbonyl, or unsubstituted aryloxycarbonyl[,];

or a pharmaceutically acceptable salt thereof.

~~and the compounds can exist as individual stereoisomers or as mixtures of stereoisomers~~.

2. (Cancelled)

3. (Cancelled)

4. (Original) The compound of Claim 1, wherein Ar is 3-pyridinyl.

5-10. (Cancelled)

11. (Original) The compound of Claim 1 wherein j is 0 or 1.

12. (Original) The compound of Claim 1 wherein j is 0.

13. (Cancelled)

14. (Cancelled)

15. (Original) The compound of Claim 1, having a structure as in Formula 2, wherein the carbon at which the azabicyclic ring is attached to the Ar moiety has *R* stereochemistry.

16. (Original) The compound of Claim 1, having a structure as in Formula 2, wherein the carbon at which the azabicyclic ring is attached to the Ar moiety has *S* stereochemistry.

17. (Cancelled)

18. (Currently Amended) A compound selected from the group consisting of:





wherein:

wherein Z_j refers to j number of Z substituents, which substituents can be present at any carbon atom on the azabicyclic ring,

j is 0, 1, or 2,

each Z is, individually, ~~a substituent species~~ selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, heterocyclyl, substituted heterocyclyl, cycloalkyl, substituted cycloalkyl, aryl ~~(including heteroaryl)~~, substituted aryl ~~(including heteroaryl)~~, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, -OR', -NR'R", $-CF_3$, -CN, $-NO_2$, -C≡C[$_2$]R', -SR', $-N_3$, -C(=O)NR'R", -NR'C(=O) R", -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R")$_r$C(=O)R', -O(CR'R")$_r$NR"C(=O)R', -O(CR'R")$_r$NR"SO_2R', -OC(=O)NR'R", -NR'C(=O)O R", $-SO_2$R', $-SO_2$NR'R", and -NR'SO_2R"[,];

where R' and R" are individually hydrogen, lower alkyl ~~(e.g., straight chain or branched alkyl including C_1-C_8, preferably C_1-C_6, such as methyl, ethyl, or isopropyl)~~, cycloalkyl, heterocyclyl, aryl, or arylalkyl ~~(such as benzyl)~~, and r is an integer from 1 to 6[,]; or R' and R" can combine with the atoms to which they are attached to form a ~~cyclic functionality~~ 3- to 7-membered saturated or unsaturated ring[,];

the term "substituted" ~~as applied to alkyl, aryl (including heteroaryl), cycloalkyl and the like~~ refers to one or more ~~the~~ substituents ~~described above, starting with halo and ending with -NR'SO_2R"~~ selected from the group consisting of halo, -OR', -NR'R", $-CF_3$, -CN, $-NO_2$, -C≡CR', -SR', $-N_3$, -C(=O)NR'R", -NR'C(=O) R", -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R")$_r$C(=O)R', -O(CR'R")$_r$NR"C(=O)R', -O(CR'R")$_r$NR"SO_2R', -OC(=O)NR'R", -NR'C(=O)O R", $-SO_2$R', $-SO_2$NR'R", and -NR'SO_2R"[,];

where R' and R" individually are as defined;

R is hydrogen, unsubstituted lower alkyl, unsubstituted arylalkyl~~, acyl~~, unsubstituted alkoxycarbonyl, or unsubstituted aryloxycarbonyl[,]; and

the hashed bond indicates the presence or absence of a double bond[, and];

or a pharmaceutically acceptable salt thereof.

~~the compounds can exist as individual stereoisomers or mixtures of stereoisomers.~~

19-69. (Cancelled)

70. (Currently amended) A pharmaceutical composition comprising:

a) a compound of Claim 1,

b) one or more of an antineoplastic agent and[/or] a VEGF-inhibitor, and

c) a pharmaceutically acceptable carrier.

71-72. (Cancelled)

73. (New) The compound of claim 1 wherein Ar is unsubstituted pyridine.

74. (New) The compound of claim 1, wherein Ar is pyridine substituted with one or more Z, individually selected from the group consisting of alkyl, amino, aryl, halo, and -OR', where R' is selected from alkyl or aryl.

75. (New) The compound of claim 74 wherein said aryl is phenyl.

76. (New) The compound of claim 74 wherein said alkyl is methyl or isopropyl.

77. (New) The compound of claim 1 wherein the compound is of Formula 1.

78. (New) The compound of claim 1 wherein the compound is of Formula 2.

79. (New) A compound selected from the group consisting of:
6-(3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
6-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
6-(6-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(6-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(6-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(6-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,

6-(5-isopropoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(5-isopropoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(5-isopropoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(5-isopropoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
6-(5-phenoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(5-phenoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(5-phenoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(5-phenoxy-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
6-(5-phenyl-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(5-phenyl-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(5-phenyl-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
7-(5-phenyl-3-pyridinyl)-3-azabicyclo[3.3.1]nonane,
6-(6-chloro-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
7-(6-chloro-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene,
6-(6-chloro-3-pyridinyl)-3-azabicyclo[3.3.1]nonane, and
7-(6-chloro-3-pyridinyl)-3-azabicyclo[3.3.1]nonane
or a pharmaceutically acceptable salt thereof.